Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

The experimental treatment, TERN-601, is part of the second generation of weight-loss drugs, which aim to offer a more ...

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also ...

A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Terns Pharmaceuticals’ weight-loss pill has proved effective in a small trial, but still has much to prove before it can ...

Novo Nordisk stock rose moderately Wednesday after the pharma giant said its new weight-loss drug, amycretin, outperformed ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.